+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Endocarditis - Pipeline Insight, 2021

  • ID: 5237637
  • Clinical Trials
  • September 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • ContraFect
  • Venus Remedies
This “Endocarditis - Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Endocarditis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Endocarditis Understanding

Endocarditis: Overview


Endocarditis is a rare condition that involves inflammation of the heart lining, heart muscles, and heart valves. It's most commonly caused by bacteria entering the blood and travelling to the heart. The initial symptoms of endocarditis are similar to flu and include a high temperature, chills, headache, and joint and muscle pain. The infection if left untreated, damages the heart valves and disrupts the normal flow of blood through the heart. The diagnosis of endocarditis is done through blood cultures before antibiotics are started. Treatment of endocarditis is based on specific drugs or combinations of drugs, depending upon the bacterium responsible for the infection. Medications include intravenous infusion of high doses of appropriate antibiotic drugs.

"Endocarditis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endocarditis pipeline landscape is provided which includes the disease overview and Endocarditis treatment guidelines. The assessment part of the report embraces, in depth Endocarditis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endocarditis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Endocarditis R&D. The therapies under development are focused on novel approaches to treat/improve Endocarditis.

Endocarditis Emerging Drugs Chapters


This segment of the Endocarditis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endocarditis Emerging Drugs


VRT 001-V: Venus Remedies


VRT 001-V is an oral antibiotic based on stealth targeted nanoparticle (STN) technology. The product is designed to meet unmet need of shifting patients from IV to oral therapy in infections caused by both gram-positive cocci and gram-negative cocci. The drug is in preclinical studies for the treatment of Streptococcal endocarditis; and Staphylococcal infections.

Exebacase: ContraFect


Exebacase (CF-301) is a lysin with potent activity against Staphylococcus aureus. The drug is in Phase III clinical studies for the treatment of patients with Staphylococcus aureus bacteremia, including right-sided endocarditis.

Endocarditis: Therapeutic Assessment


This segment of the report provides insights about the different Endocarditis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Endocarditis


There are approx. 2+ key companies which are developing the therapies for Endocarditis. The companies which have their Endocarditis drug candidates in the most advanced stage, i.e. Phase III include, ContraFect.

Phases


This report covers around 2+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Endocarditis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Endocarditis: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Endocarditis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endocarditis drugs.

Endocarditis Report Insights

  • Endocarditis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Endocarditis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Endocarditis drugs?
  • How many Endocarditis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endocarditis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Endocarditis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Endocarditis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • ContraFect
  • Venus Remedies

Key Products

  • Exebacase
  • VRT 001-V
This product will be delivered within 1 business day.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ContraFect
  • Venus Remedies

IntroductionExecutive Summary
Endocarditis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Endocarditis - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis

Exebacase: ContraFect
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical/Discovery Stage Products
  • Comparative Analysis

VRT 001-V: Venus Remedies
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Endocarditis Key CompaniesEndocarditis Key ProductsEndocarditis- Unmet NeedsEndocarditis- Market Drivers and BarriersEndocarditis- Future Perspectives and ConclusionEndocarditis Analyst ViewsAppendix
List of Tables
Table 1 Total Products for Endocarditis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Endocarditis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • ContraFect
  • Venus Remedies
Note: Product cover images may vary from those shown